The estimated Net Worth of Samuel E Navarro is at least $689 Thousand dollars as of 21 June 2021. Mr. Navarro owns over 25,000 units of Biosig Technologies Inc stock worth over $69,440 and over the last 8 years he sold BSGM stock worth over $0. In addition, he makes $619,381 as Independent Director at Biosig Technologies Inc.
Sign up
Mr. Navarro BSGM stock SEC Form 4 insiders trading
Samuel has made over 6 trades of the Biosig Technologies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of BSGM stock worth $11,200 on 21 June 2021.
The largest trade he's ever made was exercising 25,000 units of Biosig Technologies Inc stock on 21 June 2021 worth over $11,200. On average, Samuel trades about 4,917 units every 62 days since 2016. As of 21 June 2021 he still owns at least 155,000 units of Biosig Technologies Inc stock.
You can see the complete history of Mr. Navarro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Samuel Navarro biography
Samuel E. Navarro serves as Independent Director of the Company. Mr. Navarro has served as our director since June 21, 2019. Mr. Navarro has been serving as ViralClear’s director since April 2020. Mr. Navarro has over 30 years of experience in investment banking and medical technology. He currently serves as managing partner of Gravitas Healthcare, LLC, a strategic advisory firm that specializes in emerging growth medical device companies. Since its founding in 2008, the firm has completed over 30 strategic partnership transactions with some of the largest medical device companies in the industry. From 2005 through 2008, Mr. Navarro served as a managing director and global head of Medical Technology Investment Banking at Cowen & Company. From 2001 through 2005, Mr. Navarro served as a senior portfolio manager at The Galleon Group running the Galleon Healthcare Fund. From 1998 through 2001, he was global head of Healthcare Investment Banking at ING Barings, and prior to that, he was senior medical technology research analyst at UBS, Furman Selz and Needham & Company. From March 2014 to January 2017, Mr. Navarro served as a board director on the Audit and Nominating and Governance Committees of Derma Sciences, Inc. Since May 2018, Mr. Navarro has been serving on the board of directors of StrataSkin Sciences, Inc. Mr. Navarro serves or has served on the board of directors other medical device companies, such as Arstasis, Dextera Surgical, Fixes-4-Kids, Jomed, MicroTherapeutics, and one non-medical company, Pixelux Entertainment. Mr. Navarro also served in the past as an advisory board member of OrthoPediatrics. Mr. Navarro received an MBA in finance from The Wharton School at the University of Pennsylvania. He also holds a master’s degree in engineering from Stanford University and a bachelor’s degree in engineering from the University of Texas at Austin.
What is the salary of Samuel Navarro?
As the Independent Director of Biosig Technologies Inc, the total compensation of Samuel Navarro at Biosig Technologies Inc is $619,381. There are 3 executives at Biosig Technologies Inc getting paid more, with Kenneth Londoner having the highest compensation of $5,034,850.
How old is Samuel Navarro?
Samuel Navarro is 64, he's been the Independent Director of Biosig Technologies Inc since 2019. There are 4 older and 8 younger executives at Biosig Technologies Inc. The oldest executive at Biosig Technologies Inc is Dr. Budimir S. Drakulic Ph.D., 71, who is the Chief Scientist.
What's Samuel Navarro's mailing address?
Samuel's mailing address filed with the SEC is C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT, CT, 06880.
Insiders trading at Biosig Technologies Inc
Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer, and Jerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.
What does Biosig Technologies Inc do?
biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.
What does Biosig Technologies Inc's logo look like?
Complete history of Mr. Navarro stock trades at STRATA Skin Sciences Inc and Biosig Technologies Inc
Biosig Technologies Inc executives and stock owners
Biosig Technologies Inc executives and other stock owners filed with the SEC include:
-
Kenneth Londoner,
Executive Chairman of the Board, Chief Executive Officer -
Steven Chaussy,
Chief Financial Officer -
Kenneth L. Londoner M.B.A., MBA,
Founder, CEO & Exec. Chairman -
Samuel Navarro,
Independent Director -
Jeffrey O'Donnell,
Lead Independent Director -
Martha Pease,
Independent Director -
Andrew Filler,
Independent Director -
David Weild,
Independent Director -
Patrick Gallagher,
Independent Director -
Donald Foley,
Independent Director -
Anthony Zook,
Director -
Manasi Patwardhan,
Director of Strategic Planning -
Olivier Chaudoir,
Senior Director of Marketing -
Julie Stephenson,
Vice President - Clinical Affairs, Senior Director of Clinical Affairs -
Andrew Ballou,
Vice President - Investor Relations -
John Kowalski,
Vice President - Sales -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven Chaussy,
Chief Financial Officer -
Natasha Drapeau,
Exec. VP -
Brenda Castrodad,
Director of HR -
Lora Mikolaitis,
VP of Admin. -
Dr. Budimir S. Drakulic Ph.D.,
Chief Scientist -
Steven Eric Abelman,
Director -
Steve Chaussy,
Chief Financial Officer -
Roy T Tanaka,
Director -
Lora Mikolaitis,
10% owner -
Seth H. Z. Fischer,
Director -
Joseph Rafferty,
Chief Commercialization Offcr -
Jerome B Zeldis,
Director -
Asher Holzer,
Director -
Gregory D Cash,
President and CEO -
James L Klein,
Director -
James J Barry,
Director -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven J Buhaly,
Chief Financial Officer -
Frederick Hrkac,
Director -
Donald Browne,
Director -
Christopher Allen Baer,
Director